Status:

RECRUITING

Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus

Lead Sponsor:

Zunyi Medical College

Conditions:

STEMI - ST Elevation Myocardial Infarction

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

To manage the ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture, triggers platelet activation/aggregation and thrombin generation, requires dual (platelet and coagulation) pa...

Detailed Description

The Prophylactic Rivaroxaban Therapy for Post STEMI Complicating Left VENtricular Thrombus (PREVENT) study is designed to investigate the safety and efficacy of Century Clot-guided additional low-dose...

Eligibility Criteria

Inclusion

  • Ischemic chest discomfort for at least 30 minutes, with at least 1-mm (0.1-mv) ST-segment elevation in anterior leads on a standard 12-lead electrocardiogram.
  • Patients provide written informed consent prior to enrollment.

Exclusion

  • Intracranial, gastrointestinal, or urogenital bleeding within 6 months
  • Requiring OAC therapy (eg, atrial fibrillation, deep vein thrombosis, pulmonary thromboembolism);
  • Bleeding diathesis, thrombocytopenia (platelet \<100,000/mL) or hemoglobin \<10 g/dL, and CRUSADE score-based high bleeding risk
  • Hepatic dysfunction (serum liver enzyme\>3 times the normal limit)
  • Renal failure (eGFR \<15 ml/min/1.73m2 or requiring dialysis)
  • Severe chronic obstructive pulmonary disease
  • Severe bradycardia (sick sinus syndrome or high degree atrioventricular block without pacemaker protection)
  • Drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin
  • Life expectancy \< 1 year

Key Trial Info

Start Date :

April 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2027

Estimated Enrollment :

374 Patients enrolled

Trial Details

Trial ID

NCT06013020

Start Date

April 1 2024

End Date

December 31 2027

Last Update

March 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China, 563003